Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS. Wu X, et al. Among authors: severgnini m. Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21. Cancer Immunol Res. 2017. PMID: 28003187 Free PMC article.
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A, Rodig SJ, Hodi FS, Morgan JA, Merriam P, Wagner AJ, Shapiro GI, George S. Ben-Ami E, et al. Among authors: severgnini m. Cancer. 2017 Sep 1;123(17):3285-3290. doi: 10.1002/cncr.30738. Epub 2017 Apr 25. Cancer. 2017. PMID: 28440953 Free PMC article. Clinical Trial.
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD. Mahmood U, et al. Among authors: severgnini m. Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):134-144. doi: 10.1016/j.ijrobp.2020.08.018. Epub 2020 Aug 8. Int J Radiat Oncol Biol Phys. 2021. PMID: 32781104 Free PMC article. Clinical Trial.
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC.
Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A, Paweletz C, Supplee J, Jänne PA, Severgnini M, Awad MM, Walt DR. Keegan A, et al. Among authors: severgnini m. J Immunother Cancer. 2020 Oct;8(2):e000678. doi: 10.1136/jitc-2020-000678. J Immunother Cancer. 2020. PMID: 33020238 Free PMC article.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Nayak L, et al. Among authors: severgnini m. Clin Cancer Res. 2021 Feb 15;27(4):1048-1057. doi: 10.1158/1078-0432.CCR-20-2500. Epub 2020 Nov 16. Clin Cancer Res. 2021. PMID: 33199490 Free PMC article. Clinical Trial.
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, Rahma OE. Tyan K, et al. Among authors: severgnini m. Cancer Immunol Immunother. 2021 Aug;70(8):2209-2221. doi: 10.1007/s00262-021-02855-1. Epub 2021 Jan 22. Cancer Immunol Immunother. 2021. PMID: 33481042 Free PMC article.
168 results